Navafenterol

DB19195InvestigationalSmall molecule

Navafenterol is under investigation in clinical trial NCT02971293 (Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871).

Mechanism: Pharmacologically active on Muscarinic acetylcholine receptor M3 and Beta-2 adrenergic receptor
Curator reviewed
Formula / weight: C₃₈H₄₂N₆O₆S₂ · 742.91 g/mol (avg)
Also known as: 2-thiopheneacetic acid, .alpha.-hydroxy-.alpha.-2-thienyl-, trans-4-((3-(5-((((2r)-2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl)amino)methyl)-1h-benzotriazol-1-yl)propyl)methylamino)cyclohexyl ester · Trans-4-((3-(5-((((2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydro-5- quinolinyl)ethyl)amino)methyl)-1h-benzotriazol-1-yl)propyl)(methyl)amino)cyclohexyl hydroxy(di-2-thienyl)acetate
Code names: AZD-8871 · LAS-191351

Resolves to

Compound

UNIIU29GY32XJ4CAS1435519-06-4ChEMBLCHEMBL4297483

Structure

InChIKeyZNKWRAKPQQZLNX-ZDQHWEPJSA-NSMILESCN(CCCN1N=NC2=CC(CNC[C@H](O)C3=C4C=CC(=O)NC4=C(O)C=C3)=CC=C12)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1

Targets

P20309CHRM3P07550ADRB2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Navafenterol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account